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SUMMARY 
The levels of the maternal serum markers alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG), and 
unconjugated oestriol (uE,) in 35 pregnant women with early second-trimester oligohydramnios differed from those 
in a reference population of 1699 singleton pregnancies. Maternal serum AFP levels above the 95th centile of the 
population distribution were observed in 80 per cent (16120) of oligohydramnios cases with a normal fetus and in 
only 20 per cent (3/15) of the cases with a fetus displaying urogenital tract malformations. Elevated levels of hCG 
(above the 95th centile) and decreased levels of uE, (below the fifth centile) were encountered in 26 per cent (9/35) 
and 17 per cent (6/35) of the women, irrespective of the fetal condition. The abnormal profile of the serum markers 
in early second-trimester oligohydramnios resulted in 57 per cent (20 out of 35) of,screen-positive cases for either 
fetal Down’s syndrome or neural tube defects, compared with 8.4 per cent (143 out of 1699) in the reference 
population. 
KEY woms-Second-trimester oligohydramnios, alpha-fetoprotein, human chorionic gonadotrophin, unconjugated 
oestriol, maternal serum. 
INTRODUCTION 
The simultaneous measurement of maternal 
serum alpha-fetoprotein (AFP), human chorionic 
gonadotrophin (hCG), and unconjugated oestriol 
(uE3) concentrations is used for second-trimester 
screening for fetal Down’s syndrome (Wald et al., 
1992; Haddow et al., 1992; Cheng et al., 1993). 
Apart from fetal chromosomal abnormalities, 
adverse pregnancy outcome and various complica- 
tions of pregnancy are associated with abnormal 
concentrations of these serum markers (Beekhuis 
et al., 1992; Cuckle et al., 1992). In early second- 
trimester oligohydramnios, usually raised maternal 
serum AFP levels are encountered (Dyer et al., 
1987; Richards et al., 1988; Los et al., 1992). The 
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rise of the maternal serum AFP levels in this 
condition has been shown to be of amniotic fluid 
origin (Los et al., 1992). Since placental insuf€i- 
ciency has been established in a significant number 
of oligohydramnios patients (Hackett et al., 1987), 
we subjected stored serum samples of oligohy- 
dramnios patients to additional measurement of 
hCG and uE3, originating from the placenta and 
the feto-placental unit, respectively (Hay, 1988; 
Canick et al., 1988), in order to study the profile of 
the placental markers in oligohydramnios. The 
scores of the three markers were introduced in the 
software package ‘alpha’ for risk estimates for fetal 
Down’s syndrome and neural tube defects. 
MATERIAL AND METHODS 
Thirty-nine patients with second-trimester oligo- 
hydramnios between 15 and 20 weeks of gesta- 
tional age were detected in a 4-year period among 
566 F. J. LOS ET A.L.. 
Table :-Fetal diagnosis in oligohydramnios patients: (i) oligohydramnios with associated 
fetal malformations (oligo +), and (ii) oligohydramnios without associated fetal malformations 
(oligo - ) 
Group N Fetal diagnosis 
Oligo+ 6 Syndromes featuring bilateral renal agenesis 
5 
2 
Obstructive uropathy due to urethral obstruction 
Chromosomal abnormalities with a.0. renal agenesiddysplasia 
-unbalanced translocation (8;ll) mat resulting in &somy i l  (q21 +qter) 
-69.XXX 
1 Multicystic kidney disease IIB 
1 
6 No malformations; growth retardation 
Unilateral renal agenesislcontralateral renal dysplasia 
Oligo - 14 No malformations; normal growth 
a.o.=amongst others. 
5000 pregnant women referred to us for ultra- 
sound evaluation. In 35 of them, it was possible to 
obtain a serum sample with informed consent. The 
serum samples were stored at - 80°C until assay 
and underwent only two thawinglfreezing proce- 
dures for this investigation. The technique of ultra- 
sound investigation has been described in detail 
before (Los et al., 1992). The diagnosis of oligo- 
hydramnios was established when the largest and 
nearly always the only pocket of amniotic fluid 
measured up to 2 cm (Chamberlain et a/., 1984). 
The reference population consisted of 1699 women 
with singleton pregnancies and ultrasonographi- 
cally determined gestational ages between 15 and 
20 weeks. From various hospitals the serum 
samples of these women had been submitted for 
measurement of AFP, hCG, and uE, concentra- 
tions, without a thawinglfreezing procedure. 
AFP, hCG, and uE, were assayed with the 
Amerlex M second-trimester radioimmuno- 
assay (RIA) kits for AFP, hCG, and free oestriol 
(Amersham). All concentrations were expressed as 
multiples of the median values (MOM) of the 
reference population for the respective week of 
gestation. 
Risk calculations for fetal Down’s syndrome 
and fetal neural tube defects were performed with 
the software package ‘alpha’, based on maternal 
age and the trivariate Gaussian distribution of log 
AFP, log hCG, and linear uE, concentrations 
(Wald et al., 1988). Cut-off points for a positive 
test were taken as a risk of 1:250 or higher for 
fetal Down’s syndrome and an AFP level at or 
exceeding 2.5 MOM. 
Statistical analysis allowed for the use of para- 
metric tests since the serum marker levels have 
been shown to fit (log) Gaussian distributions 
(Cuckle et al., 1987; Wald et al., 1988; Crossley 
et al., 1993). 
RESULTS 
The oligohydramnios cases consisted of 35 
patients (the group oligo f ); 15 displayed associ- 
ated fetal malformations on ultrasound investiga- 
tion (the group oligo+), whereas 20 patients had 
no fetal malformations except intrauterine growth 
retardation in six cases (the group oligo - ; Table 
I). Autopsy of the fetus confirmed the previous 
ultrasound diagnosis in 31 cases; in two cases no 
autopsy was available, and in the remaining two 
cases a live infant was born. The levels of AFP, 
hCG, and uE, in the groups oligo+ and oligo - 
are presented in Fig. 1 and Table 11. The median 
AFP level in both oligohydramnios groups was 
raised, compared with that in the reference popu- 
lation, and was higher in the group oligo - than in 
the group ohgo+. AFP levels above the 95th 
centile were observed in 16 of the 20 [80 per cent; 
95 per cent confidence interval (CI) 56.3-94.3 per 
cent] women of the group oligo - , and in only 3 of 
15 (20 per cent; 95 per cent CI 4.348.1 per cent) 
women in the group oligo+. The median hCG 
level in the group oligo f was raised and the 
distribution of values was wide with a high pro- 
portion of values above the 95th centile (9135; 25.7 
per cent; 95 per cent CI 120543.3 per cent). 
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Fig. l--levels (in MOM) of AFP (log scale), hCG (log scale), 
and uE, (linear scale) in 35 patients with second-trimester 
oligohydrarnnios. 0 ,  0, 0 denote patients with abnormal, 
normal, and normal but growth-retarded fetuses, respectively. 
The fifth and 95th centiles of each serum marker in the 
reference population are indicated 
Median uE3 levels were unremarkable, but the 
distribution was also wide with a significant pro- 
portion of values below the fifth centile (6/35, 17.1 
per cent; 95 per cent CI 66-33-7 per cent). In 57 
per cent of the cases of oligohydramnios (20/35) a 
screen-positive result was obtained, either for fetal 
Down's syndrome or for neural tube defects, com- 
pared with 8.4 per cent of the cases (143/1699) of 
the reference population. 
DISCUSSION 
Raised maternal serum AFP levels in second- 
trimester oligohydramnios are mainly associated 
with the presence of a normal fetus, and originate 
from the diminished amniotic fluid compartment 
(Los et af., 1992). In the 15 cases of oligohydram- 
nios with associated fetal malformations, a renal 
or a post-renal fetal anuridoliguria was present. 
An increased AFP transfer from the amniotic fluid 
compartment towards the maternal compartment, 
modulated by the presence or absence of fetal 
diuresis, explains the distinct distributions of AFP 
levels in-between the groups oligo+ and oligo - , 
and between these groups and the reference 
population. 
The concentrations of hCG show a higher 
median level and a wider distribution of values in 
the oligohydramnios patients than in the reference 
population, resulting in an increased number of 
elevated levels, known to be associated with pla- 
cental pathology (Bogart et al., 1987; Hay, 1988; 
Beekhuis et al., 1992). The uE3 distribution in 
oligohydramnios shows a normal median level but 
a wider distribution of values than that in the 
reference population resulting in a significant num- 
ber of decreased levels. Decreased uE3 levels are, at 
least in the third trimester of pregnancy, associated 
with reduced placental function (Chard et af., 
1985; Perry et al., 1986). 
Table 11-AFP, hCG, and uE3 levels in the reference population and in the oligo- 
hydramnios groups. NS = statistically not s i d c a n t  (P>0.05, two-tailed) 
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Early second-trimester oligohydramnios rep- 
resents a serious complication of pregnancy 
associated with an abnormal profile of the serum 
markers AFP, hCG, and uE3, resulting in a signs- 
cant increased percentage (57 per cent) of screen- 
positive cases for fetal neural tube defects and/or 
Down’s syndrome. 
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